FDA Warns of Aseptic Meningitis Risk With Use of Lamotrigine
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Warns of Aseptic Meningitis Risk With Use of Lamotrigine

ROCKVILLE, Md -- August 12, 2010 -- The US Food and Drug Administration (FDA) today warned that the drug lamotrigine (Lamictal), approved to treat seizures and bipolar disorder, can cause aseptic meningitis.

The agency is working with the drug's manufacturer, GlaxoSmithKline, to update the prescribing information and patient medication guide to include this risk.

Aseptic meningitis has a number of causes including, but not limited to, viruses, toxic agents, some vaccines, autoimmune diseases, and certain medications, including lamotrigine.

Symptoms can include headache, fever, chills, nausea, vomiting, stiff neck, and sensitivity to light. Hospitalisation may be required.

In suspected cases of meningitis, the underlying cause should be rapidly diagnosed so that treatment can be promptly initiated. Discontinuation of lamotrigine should be considered if no other clear cause of meningitis is identified.

"Aseptic meningitis is a rare but serious side effect of [lamotrigine] use," said Russell Katz, MD, Division of Neurology Products in the FDA's Center for Drug Evaluation and Research, Rockville, Maryland. "Patients that experience symptoms should consult their healthcare professional immediately."

The FDA became aware of the association between lamotrigine and aseptic meningitis through routine adverse event monitoring and communications with the drug's manufacturer. Since the drug's approval in December 1994 through November 2009, there were 40 cases of aseptic meningitis identified in patients taking lamotrigine. The symptoms were reported to occur within 1 to 42 days after starting lamotrigine. Thirty-five of the 40 patients required hospitalisation. In most cases, symptoms ended after lamotrigine was discontinued. In 15 cases, symptoms, often more severe, returned when patients restarted the drug.

SOURCE: US Food and Drug Administration

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities